Advisory Council on the Misuse of Drugs. (2024) A review of the evidence on the use and harms of xylazine, medetomidine and detomidine. London: Advisory Council on the Misuse of Drugs.
| Preview | Title | Contact |
|---|---|---|
|
PDF (A review of the evidence on the use and harms of xylazine, medetomidine and detomidine)
- Published Version
458kB |
This report reviews the evidence of use and the harms of xylazine in the UK and considers whether it should be controlled by the Misuse of Drugs Act 1971. Evidence of Illicit use in the UK of the related compounds medetomidine and detomidine was also sought, as this has been reported in other countries.
The report provides recommendations for the classification and scheduling of xylazine, following a thorough review of the evidence available.
[See also, UK Government response to the ACMD’s advice on xylazine and related compounds, published 21 March 2024]
B Substances > New (novel) psychoactive substances > Other novel substances > Xylazine, detomidine, medetomidine
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Harm reduction > Substance use harm reduction
MM-MO Crime and law > Substance use laws > Drug laws
N Communication, information and education > Recommendations
VA Geographic area > Europe > United Kingdom
Repository Staff Only: item control page